About AstraZeneca Gothenburg 2016 event

Over the last few years, we have been working to re-build AstraZeneca Gothenburg as a centre for research in life sciences in the Nordic countries. We now have significant collaborations with key stakeholders across the region. The event aims to bring everyone together and the participation and engagement is a testament to our ability to take a leadership role in life science research.

Jan-Olof Jacke President, AstraZeneca Sweden

On 31 May 2016, we hosted the first AstraZeneca Exchange Gothenburg event at our R&D centre in Gothenburg, Sweden. The event brought together representatives from across the Nordic Life Science community including industry, biotech, academia, Government and the public sector.

Gothenburg is one of AstraZeneca’s three global R&D centres, alongside our sites in Cambridge in the UK and Gaithersburg in the US. Each site is located close to a globally recognized bioscience cluster to allow us to benefit from a wider ecosystem of universities, researchers, biotechs and peers. This is because we know that innovation doesn’t happen in isolation. We already benefit from collaboration with others across the Life Science sector and we build on each other’s successes.

Our joint successes matter not only for our companies, but for our region and its economy – Gothenburg, Sweden and our neighbouring countries.

Our aim with AstraZeneca Exchange Gothenburg 2016 was to support the growing Life Science ecosystem in the Nordics, stimulate innovation and make the region as strong as it can be in the biotechnology sector through networking, interactive discussion and knowledge sharing.

The day was made up of a combination of plenary sessions and informal ‘discussion stations’. Speakers at the event included Leif Johansson, Chairman, AstraZeneca, Anders Lönnberg, Swedish National coordinator for Life Sciences and Member of Parliament and Carl Borrebaeck, Vice President and Professor of Immunotechnology, Lund University.

With AstraZeneca Exchange Gothenburg we hope to demonstrate that AstraZeneca is truly open to ideas and emerging science that takes place outside our laboratories. People can read brochures and go online to get a sense of AstraZeneca, but there is no substitute for human interaction. And it’s when scientists start to talk to scientists that sparks really begin to fly.

Shaun Grady Vice-President, Business Development Operations, AstraZeneca